Patient characteristics
| Variable . | Total . | Training set . | Validation set . | P . |
|---|---|---|---|---|
| n = 2207 (%) . | n = 1765 (%) . | n = 442 (%) . | ||
| Age group at transplant, y | .327 | |||
| ≤30 | 339 (15.4) | 265 (15.0) | 74 (16.7) | |
| >30-40 | 340 (15.4) | 277 (15.7) | 63 (14.3) | |
| >40-50 | 480 (21.7) | 376 (21.3) | 104 (23.5) | |
| >50-60 | 631 (28.6) | 509 (28.8) | 122 (27.6) | |
| >60 | 417 (18.9) | 338 (19.2) | 79 (17.9) | |
| Sex | .572 | |||
| Male | 925 (41.9) | 734 (41.6) | 191 (43.2) | |
| Female | 1282 (58.1) | 1031 (58.4) | 251 (56.8) | |
| Source of stem cells | .279 | |||
| BM | 1349 (61.1) | 1061 (60.1) | 288 (65.2) | |
| Peripheral blood | 356 (16.1) | 292 (16.5) | 64 (14.5) | |
| BM + peripheral blood | 7 (0.3) | 6 (0.3) | 1 (0.2) | |
| Cord blood | 495 (22.4) | 406 (23.0) | 89 (20.1) | |
| Time from diagnosis to transplant | .707 | |||
| ≤6 mo | 793 (35.9) | 638 (36.1) | 155 (35.1) | |
| >6 mo | 1392 (63.1) | 1108 (62.8) | 284 (64.3) | |
| Uncertain/missing | 22 (1.0) | 19 (1.1) | 3 (0.7) | |
| Year of transplant | .441 | |||
| 1996-2006 | 718 (32.5) | 581 (32.9) | 137 (31.0) | |
| 2007-2016 | 1489 (67.5) | 1184 (67.1) | 305 (69.0) | |
| Diagnosis | .652 | |||
| AML | 868 (39.3) | 703 (39.8) | 165 (37.3) | |
| ALL | 371 (16.8) | 296 (16.8) | 75 (17.0) | |
| ATL | 130 (5.9) | 102 (5.8) | 28 (6.3) | |
| CML | 124 (5.6) | 94 (5.3) | 30 (6.8) | |
| MDS | 342 (15.5) | 274 (15.5) | 68 (15.4) | |
| Other leukemia | 31 (1.4) | 23 (1.3) | 8 (1.8) | |
| MPN | 38 (1.7) | 28 (1.6) | 10 (2.3) | |
| NHL/HL/other lymphoma | 294 (13.3) | 236 (13.4) | 58 (13.1) | |
| MM/PCD | 9 (0.4) | 9 (0.5) | 0 (0.0) | |
| Follow-up of survivors | ||||
| Median time, month (range) | 52.5 (0.5-244.6) | 57.6 (0.5-244.6) | 58.6 (0.7-235.4) | .743 |
| Variable . | Total . | Training set . | Validation set . | P . |
|---|---|---|---|---|
| n = 2207 (%) . | n = 1765 (%) . | n = 442 (%) . | ||
| Age group at transplant, y | .327 | |||
| ≤30 | 339 (15.4) | 265 (15.0) | 74 (16.7) | |
| >30-40 | 340 (15.4) | 277 (15.7) | 63 (14.3) | |
| >40-50 | 480 (21.7) | 376 (21.3) | 104 (23.5) | |
| >50-60 | 631 (28.6) | 509 (28.8) | 122 (27.6) | |
| >60 | 417 (18.9) | 338 (19.2) | 79 (17.9) | |
| Sex | .572 | |||
| Male | 925 (41.9) | 734 (41.6) | 191 (43.2) | |
| Female | 1282 (58.1) | 1031 (58.4) | 251 (56.8) | |
| Source of stem cells | .279 | |||
| BM | 1349 (61.1) | 1061 (60.1) | 288 (65.2) | |
| Peripheral blood | 356 (16.1) | 292 (16.5) | 64 (14.5) | |
| BM + peripheral blood | 7 (0.3) | 6 (0.3) | 1 (0.2) | |
| Cord blood | 495 (22.4) | 406 (23.0) | 89 (20.1) | |
| Time from diagnosis to transplant | .707 | |||
| ≤6 mo | 793 (35.9) | 638 (36.1) | 155 (35.1) | |
| >6 mo | 1392 (63.1) | 1108 (62.8) | 284 (64.3) | |
| Uncertain/missing | 22 (1.0) | 19 (1.1) | 3 (0.7) | |
| Year of transplant | .441 | |||
| 1996-2006 | 718 (32.5) | 581 (32.9) | 137 (31.0) | |
| 2007-2016 | 1489 (67.5) | 1184 (67.1) | 305 (69.0) | |
| Diagnosis | .652 | |||
| AML | 868 (39.3) | 703 (39.8) | 165 (37.3) | |
| ALL | 371 (16.8) | 296 (16.8) | 75 (17.0) | |
| ATL | 130 (5.9) | 102 (5.8) | 28 (6.3) | |
| CML | 124 (5.6) | 94 (5.3) | 30 (6.8) | |
| MDS | 342 (15.5) | 274 (15.5) | 68 (15.4) | |
| Other leukemia | 31 (1.4) | 23 (1.3) | 8 (1.8) | |
| MPN | 38 (1.7) | 28 (1.6) | 10 (2.3) | |
| NHL/HL/other lymphoma | 294 (13.3) | 236 (13.4) | 58 (13.1) | |
| MM/PCD | 9 (0.4) | 9 (0.5) | 0 (0.0) | |
| Follow-up of survivors | ||||
| Median time, month (range) | 52.5 (0.5-244.6) | 57.6 (0.5-244.6) | 58.6 (0.7-235.4) | .743 |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; PCD, plasma cell disease.